Immune Sera and Immunoglobulins
- Name
- Immune Sera and Immunoglobulins
- Accession Number
- DBCAT002143
- Description
Not Available
- ATC Classification
- Drugs
Drug Drug Description Palivizumab A monoclonal anti respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients. Motavizumab Investigated for use/treatment in viral infection and pediatric indications. Raxibacumab A monoclonal antibody used in conjunction with an antibacterial regimen to treat patients with inhalational anthrax caused by Bacillus anthracis and for prophylaxis of inhalational anthrax when appropriate. Rabies virus inactivated antigen, B Inactivated rabies virus antigen B is indicated for pre- and post-exposure prophylaxis against rabies. Rabies virus inactivated antigen, A Rabies virus inactivated antigen, A is an inactivated virus vacine for the intramuscular injection. It is an active immunization against rabies that can be administered pre- or post-exposure to the... Tetanus immune globulin, human A solution of antibodies used to prevent tetanus after an injury. Nebacumab Not Annotated Human cytomegalovirus immune globulin A solution of immune globulin G against cytomegalovirus used to prevent transmission of cytomegalovirus after organ transplants. Obiltoxaximab A monoclonal antibody used for prophylaxis or treatment of inhalational anthrax. Bezlotoxumab A monoclonal antibody used to reduce the recurrence of Clostridium difficile infections. Hepatitis B immune globulin An injection of immunoglobulin G (IgG) antibodies to prevent the development of chronic Hepatitis B infection. Human Rho(D) immune globulin A solution of antibodies used to prevent isoimmunization of Rho(D) negative patients exposed to Rho(D) positive blood in pregnancy or transfusion. Cilgavimab An extended half-life recombinant monoclonal IgG1κ antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization. Tixagevimab An extended half-life recombinant monoclonal IgG1κ antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization. Imdevimab Part of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19. Casirivimab Part of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19. Nirsevimab A long-acting monoclonal antibody indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. Sotrovimab A monoclonal antibody for the treatment of mild-to-moderate COVID-19 in patients at increased risk for death or hospitalization. Ansuvimab A fully human monoclonal IgG1 antibody directed against the GP1,2 surface protein of Zaire ebolavirus that is an effective treatment for Ebola virus disease. Regdanvimab A monoclonal antibody targeted against the SARS-CoV-2 spike protein used to treat patients with COVID-19 who are at risk of progressing to severe COVID-19. - Drugs & Drug Targets